News & Events COVID-19

Media Coverage of CTI's COVID-19 Work

June 4, 2020

CTI - One of Founding Contributers of NKY Coronavirus Emergency Relief Fund CTI is proud to be one of othe original contributers to a local relief fund for those affected by the pandemic. Coverage by the NKY Tribune Coverage by The Lane Report Coverage by the Cincinnati Enquirer Coverage ...

Read More

Recognizing the Regulatory Agencies Supporting the Fight Against COVID-19

May 28, 2020

The COVID-19 pandemic has spotlighted the courageous work of health care workers, first responders, delivery people, grocery store clerks and stockers, and others in the supply chain providing care, food, and medical supplies ...

Read More

CTI Partners with St. Elizabeth Healthcare and Pulmotect to Open First Hospital Site for Phase-2 Clinical Trial Targeting COVID-19

May 18, 2020

FOR IMMEDIATE RELEASE [Covington, KY / Edgewood, KY ~ May 18, 2020] – St. Elizabeth Healthcare has been selected as the first site of the FDA-approved Phase-2 COVID-19 clinical trial studying the drug PUL-042 of Pulmotect, Inc., in partnership with CTI ...

Read More

CTI Partners with Pulmotect on Two Phase-2 Trials Targeting COVID-19

May 11, 2020

FOR IMMEDIATE RELEASE [Covington, KY ~ May 11, 2020] – CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, is partnering with Pulmotect, Inc., a clinical-stage biotechnology company, on two COVID-19 phase 2 clinical trials ...

Read More

First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19

May 7, 2020

First Phase III pivotal study for an anti-GM-CSF therapy in COVID-19 patients First patient dosed in US randomized, double-blind, placebo-controlled, multi-center, Phase III study with an anti-GM-CSF monoclonal antibody which, if successful, may lead to lenzilumab product ...

Read More

CTI Clinical Research Center - A COVID-19 Vaccine Site

April 30, 2020

Over the past several weeks, the CTI Clinical Research Center (CRC) has been proactively preparing to support upcoming COVID-19 vaccine trials. With three decades of research experience and over 1,000 trials completed, the CTI ...

Read More

FDA Approves Initiation of Phase III Study of Lenzilumab in COVID-19 patients

April 15, 2020

Company intends to begin enrolling patients as soon as possible at several leading centers Phase III study enrollment to focus on adult, hospitalized patients with COVID-19 penumonia and at high risk of progression to respiratory failure ...

Read More

CTI Partners with Humanigen for Planned Phase III Study for Lenzilumab for Coronavirus Treatment

March 30, 2020

Study to tackle leading cause of death in COVID-19 patients Lenzilumab, a monoclonal antibody that neutralizes granulocyte macrophage colony stimulating factor (GM-CSF) GM-CSF is up-regulated in COVID-19 patients and may cause a harmful immune response leading to ...

Read More

How CTI Can Help Fight the Impact of COVID-19

March 27, 2020

What CTI Can Do to Help Fight the Impact of COVID-19 CTI is dedicated to helping our partners, team members, and communities work through the COVID-19 pandemic. Whether that means helping adjust programs impacted ...

Read More

Subscribe to our mailing list

* indicates required